Brevan Howard Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Brevan Howard Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+19,365	New	+$143K	﹤0.01%	1902

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brevan Howard Capital Management's RNAC Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 19,365 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #1902 among its holdings.

95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Brevan Howard Capital Management held 19,365 shares of Cartesian Therapeutics worth $202K as of Q2 2026.
Cartesian Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
Cartesian Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1902 holding.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.